Torben Schiffner

Torben Schiffner

Auto-generated profile, based on publicly available information

Torben Schiffner

Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Science
Verified
Journal Article
Closed access
DLDavid J. Leggat
David J. Leggat
CWCohen Kristen W
Cohen Kristen W
JWJordan R. Willis
Jordan R. Willis
WFWilliam J. Fulp
William J. Fulp
ADAllan DeCamp
Allan DeCamp
WSWilliam R Schief
William R Schief
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial, the HIV vaccine–priming candidate eOD-GT8 60mer adjuvanted with AS01 B had a favorable safety profile and induced VRC01-class bnAb precursors in 97% of vaccine recipients with median frequencies reaching 0.1% among immunoglobulin G B cells in blood. bnAb precursors shared properties with bnAbs and gained somatic hypermutation and affinity with the boost. The results establish clinical proof of concept for germline-targeting vaccine priming, support development of boosting regimens to induce bnAbs, and encourage application of the germline-targeting strategy to other targets in HIV and other pathogens.

17 July 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
TSTorben Schiffner
Torben Schiffner
QSQuentin Sattentau
Quentin Sattentau
LDLucy Dorrell
Lucy Dorrell
The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.

1 October 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
SBSabyasachi Baboo
Sabyasachi Baboo
JDJolene K. Diedrich
Jolene K. Diedrich
SMSalvador Martínez-Bartolomé
Salvador Martínez-Bartolomé
XWXiaoning Wang
Xiaoning Wang
TSTorben Schiffner
Torben Schiffner
JYJohn Yates
John Yates

27 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAnna Romanov
Anna Romanov
GKGrant A. Knappe
Grant A. Knappe
LRLarance Ronsard
Larance Ronsard
HSHeikyung Suh
Heikyung Suh
MOMarjan Omer
Marjan Omer
DIDarrell J. Irvine
Darrell J. Irvine
Recruitment and expansion of rare precursor B cells in germinal centers (GCs) is a central goal of vaccination to generate broadly neutralizing antibodies (bnAbs) against challenging pathogens such as HIV. Multivalent immunogen display is a well-established method to enhance vaccine-induced B cell responses, typically accomplished by using natural or engineered protein scaffolds. However, these scaffolds themselves are targets of antibody responses, with the potential to generate competitor scaffold-specific B cells that could theoretically limit expansion and maturation of “on-target” B cells in the GC response. Here, we rationally designed T-independent, DNA-origami based virus-like particles (VLPs) with optimal antigenic display of the germline targeting HIV Env immunogen, eOD-GT8, and appropriate T cell help to achieve a potent GC response. In preclinical mouse models, these DNA-VLPs expanded significantly higher frequencies of epitope-specific GC B cells compared with a state-of-the-art clinical protein nanoparticle. Optimized DNA-VLPs primed germinal centers focused on the target antigen and rapidly expanded subdominant broadly neutralizing antibody precursor B cells for HIV with a single immunization. Thus, avoiding scaffold-specific responses augments priming of bnAb precursor B cells, and DNA-VLPs are a promising platform for promoting B cell responses towards challenging subdominant epitopes.

20 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JMJacob T. Martin
Jacob T. Martin
CCChristopher A. Cottrell
Christopher A. Cottrell
AAAleksandar Antanasijevic
Aleksandar Antanasijevic
DCDiane G. Carnathan
Diane G. Carnathan
BCBenjamin J. Cossette
Benjamin J. Cossette
DIDarrell J. Irvine
Darrell J. Irvine
Following immunization, high affinity antibody responses develop within germinal centers (GCs), specialized sites within follicles of the lymph node (LN) where B cells proliferate and undergo somatic hypermutation. Antigen availability within GCs is important, as B cells must acquire and present antigen to follicular helper T cells to drive this process. However, recombinant protein immunogens such as soluble HIV envelope (Env) trimers do not efficiently accumulate in follicles following traditional immunization. Here we demonstrate two strategies to concentrate HIV Env immunogens in follicles, via the formation of immune complexes (ICs) or by employing self-assembling protein nanoparticles for multivalent display of Env antigens. Using rhesus macaques, we show that within a few days following immunization, free trimers were present in a diffuse pattern in draining LNs, while trimer ICs and Env nanoparticles accumulated in B cell follicles. Whole LN imaging strikingly revealed that ICs and trimer nanoparticles concentrated in as many as 500 follicles in a single lymph node within 2 days after immunization. Imaging of LNs collected 7 days post-immunization showed that Env nanoparticles persisted on follicular dendritic cells in the light zone of nascent germinal centers. These findings suggest that the form of antigen administered in vaccination can dramatically impact localization in lymphoid tissues and provides a new rationale for the enhanced immune responses observed following immunization with immune complexes or nanoparticles.

19 August 2025 in bioRxiv
Verified
Preprint
Open access
JHJiachen Huang
Jiachen Huang
OSOlivia M. Swanson
Olivia M. Swanson
KRKimmo Rantalainen
Kimmo Rantalainen
MFMonica L. Fernandez-Quintero
Monica L. Fernandez-Quintero
JLJohannes R. Loeffler
Johannes R. Loeffler
AWAndrew Ward
Andrew Ward
Applying cryoEM to small protein complexes is usually challenging due to their lack of features for particle alignment. Here, we characterized antibody responses to 21 kDa HIV membrane-proximal external region germline-targeting (MPER-GT) immunogens through cryoEM by complexing them with 10E8 or Fabs derived from MPER-GT immunized animals. Distinct antibody-antigen interactions were analyzed using atomic models generated from cryoEM maps. Mutagenesis screening revealed off-target mAbs that do not compete with 10E8 bind non-MPER epitopes, and the two most dominant epitopes were verified by cryoEM. The structures of 10E8-class on-target Fabs showed binding patterns that resemble the YxFW motif in the 10E8 HCDR3 loop. Additionally, we demonstrate that high-resolution maps can be generated from heterogeneous samples with pooled competing Fabs. Overall, our findings will facilitate the optimization of MPER GT-antigens and push the size limit for cryoEM-based epitope mapping with smaller antigens and heterogeneous antibody mixes.